Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110083695> ?p ?o ?g. }
- W2110083695 endingPage "8" @default.
- W2110083695 startingPage "810" @default.
- W2110083695 abstract "Studies on a series of benzoquinazoline folate analogues as inhibitors of human thymidylate synthase led to the selection of 1843U89 for further evaluation. This compound had a Ki of 90 pM versus human thymidylate synthase and was noncompetitive with (6R,S)-5,10-methylenetetrahydrofolate. It was a good substrate for the addition of the second glutamate by hog liver folylpolyglutamate synthetase, having a Vmax/Km value 7.8-fold higher than (6R,S)-tetrahydrofolate. The data indicate that 1843U89 was transported into cells via the reduced folate carrier. The Kt for 1843U89 in MOLT-4 cells was 0.33 microM, which was 3-fold lower than that for methotrexate and 16-fold lower than that for (6S-5-formyltetrahydrofolate. V/K values were 20.3 for 1843U89 versus 1.2 and 1.9 for methotrexate and (6S)-5-formyltetrahydrofolate, respectively. It was a potent inhibitor of the growth of human cells, having 50% inhibitory concentrations below 1 nM for all cell lines tested. Growth inhibition was reversed by thymidine alone, indicating that thymidylate synthase was the only site of action of this compound. Growth inhibition was not affected by (6R,S-5-formyltetrahydrofolate at concentrations below 5 microM. However, the 50% inhibitory concentration increased when the concentration in the medium was increased to 100 microM, presumably due to competition for transport. Relative to the human cell lines used, murine cell lines were 80-1300-fold less sensitive to 1843U89 and the other benzoquinazolines tested. This decreased sensitivity appeared to be due, at least in part, to decreased transport or accumulation in murine cells. Ki values for inhibition of methotrexate transport for the benzoquinazolines were 5-17-fold higher in L1210 cells than in MOLT-4 cells. 1843U89, the benzoquinazoline which was transported most efficiently and which was the most potent inhibitor of the growth of human cells, exhibited the largest difference between binding to the MOLT-4 human and L1210 murine transporter. The V/K for L1210 transport was 80-fold less than that for MOLT-4. Initial antitumor studies, using the human thymidine kinase-deficient line GC3TK- to circumvent problems associated with murine transport as well as the high circulating thymidine levels in mice, indicated that 1843U89 had marked in vivo antitumor activity." @default.
- W2110083695 created "2016-06-24" @default.
- W2110083695 creator A5029533258 @default.
- W2110083695 creator A5043794164 @default.
- W2110083695 creator A5046504243 @default.
- W2110083695 creator A5051912107 @default.
- W2110083695 creator A5070038043 @default.
- W2110083695 creator A5072876748 @default.
- W2110083695 creator A5074589892 @default.
- W2110083695 creator A5078416200 @default.
- W2110083695 creator A5085164407 @default.
- W2110083695 creator A5085403629 @default.
- W2110083695 date "1993-02-15" @default.
- W2110083695 modified "2023-09-23" @default.
- W2110083695 title "Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase." @default.
- W2110083695 cites W1484049953 @default.
- W2110083695 cites W1505630620 @default.
- W2110083695 cites W1509115195 @default.
- W2110083695 cites W1530476228 @default.
- W2110083695 cites W1536608791 @default.
- W2110083695 cites W1539628094 @default.
- W2110083695 cites W1975760215 @default.
- W2110083695 cites W1983809640 @default.
- W2110083695 cites W1991146187 @default.
- W2110083695 cites W2011809539 @default.
- W2110083695 cites W2012124146 @default.
- W2110083695 cites W2014062936 @default.
- W2110083695 cites W2017800701 @default.
- W2110083695 cites W2039545457 @default.
- W2110083695 cites W2061825609 @default.
- W2110083695 cites W2086863971 @default.
- W2110083695 cites W2143674871 @default.
- W2110083695 cites W2253033732 @default.
- W2110083695 cites W2325005109 @default.
- W2110083695 cites W235773265 @default.
- W2110083695 cites W2408913764 @default.
- W2110083695 cites W2432490060 @default.
- W2110083695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8428362" @default.
- W2110083695 hasPublicationYear "1993" @default.
- W2110083695 type Work @default.
- W2110083695 sameAs 2110083695 @default.
- W2110083695 citedByCount "34" @default.
- W2110083695 countsByYear W21100836952013 @default.
- W2110083695 countsByYear W21100836952018 @default.
- W2110083695 countsByYear W21100836952021 @default.
- W2110083695 crossrefType "journal-article" @default.
- W2110083695 hasAuthorship W2110083695A5029533258 @default.
- W2110083695 hasAuthorship W2110083695A5043794164 @default.
- W2110083695 hasAuthorship W2110083695A5046504243 @default.
- W2110083695 hasAuthorship W2110083695A5051912107 @default.
- W2110083695 hasAuthorship W2110083695A5070038043 @default.
- W2110083695 hasAuthorship W2110083695A5072876748 @default.
- W2110083695 hasAuthorship W2110083695A5074589892 @default.
- W2110083695 hasAuthorship W2110083695A5078416200 @default.
- W2110083695 hasAuthorship W2110083695A5085164407 @default.
- W2110083695 hasAuthorship W2110083695A5085403629 @default.
- W2110083695 hasConcept C112243037 @default.
- W2110083695 hasConcept C121608353 @default.
- W2110083695 hasConcept C123321153 @default.
- W2110083695 hasConcept C150757390 @default.
- W2110083695 hasConcept C153911025 @default.
- W2110083695 hasConcept C181199279 @default.
- W2110083695 hasConcept C185592680 @default.
- W2110083695 hasConcept C202751555 @default.
- W2110083695 hasConcept C203014093 @default.
- W2110083695 hasConcept C2777108182 @default.
- W2110083695 hasConcept C2779707156 @default.
- W2110083695 hasConcept C2780456651 @default.
- W2110083695 hasConcept C2781059491 @default.
- W2110083695 hasConcept C54355233 @default.
- W2110083695 hasConcept C55493867 @default.
- W2110083695 hasConcept C62112901 @default.
- W2110083695 hasConcept C81885089 @default.
- W2110083695 hasConcept C86803240 @default.
- W2110083695 hasConcept C98274493 @default.
- W2110083695 hasConceptScore W2110083695C112243037 @default.
- W2110083695 hasConceptScore W2110083695C121608353 @default.
- W2110083695 hasConceptScore W2110083695C123321153 @default.
- W2110083695 hasConceptScore W2110083695C150757390 @default.
- W2110083695 hasConceptScore W2110083695C153911025 @default.
- W2110083695 hasConceptScore W2110083695C181199279 @default.
- W2110083695 hasConceptScore W2110083695C185592680 @default.
- W2110083695 hasConceptScore W2110083695C202751555 @default.
- W2110083695 hasConceptScore W2110083695C203014093 @default.
- W2110083695 hasConceptScore W2110083695C2777108182 @default.
- W2110083695 hasConceptScore W2110083695C2779707156 @default.
- W2110083695 hasConceptScore W2110083695C2780456651 @default.
- W2110083695 hasConceptScore W2110083695C2781059491 @default.
- W2110083695 hasConceptScore W2110083695C54355233 @default.
- W2110083695 hasConceptScore W2110083695C55493867 @default.
- W2110083695 hasConceptScore W2110083695C62112901 @default.
- W2110083695 hasConceptScore W2110083695C81885089 @default.
- W2110083695 hasConceptScore W2110083695C86803240 @default.
- W2110083695 hasConceptScore W2110083695C98274493 @default.
- W2110083695 hasIssue "4" @default.
- W2110083695 hasLocation W21100836951 @default.
- W2110083695 hasOpenAccess W2110083695 @default.
- W2110083695 hasPrimaryLocation W21100836951 @default.